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a b s t r a c t
Osteoarthritis is the most common joint disease affecting roughly one sixth of the human population. It is
also the most common arthritis affecting the temporomandibular joint, often leading to severe pain and
the inability tomasticate. Animalmodels are essential to investigate the disease in part because they lend
themselves to genetic manipulation and various treatments and also because of the lack of availability
of human specimens from various stages of the disease. The wide range of osteoarthritis models alone
are a proof of its multifactorial origin. Manipulation of collagen, cytokine, matrix metalloproteinase and
small leucine-rich repeat proteoglycan genes can all have an effect on the development and persistence
of arthritis. Surgical models also exist, highlighting the importance of normal anatomy and trauma. Here
we review the English literature of murine models of temporomandibular joint arthritis with special
attention to the genetic and molecular background of osteoarthritis.
© 2016 Published by Elsevier Masson SAS on behalf of Socie´te´ franc¸aise de rhumatologie.
1. Introduction
Osteoarthritis (OA) is the most common joint disease charac-
terized by progressive softening and disintegration of the articular
cartilage. Thebasic characteristics of thedisease are similar inmany
species including humans.Murinemodels of OA are very important
in gaining more information about this disease, especially because
the presence of OA can be observed in nearly all inbred strains of
laboratory mice as part of the joint tissue’s ageing process. Animal
models are an excellent tool to investigate the molecular back-
ground and development of the disease as these arewell conserved
in animal models. However, the anatomy of the joint varies in dif-
ferentmammalian groups and so does itsmorphology and function
[1]. Therefore animalmodels have limiteduse in studying temporo-
mandibular disorders as they do not show the typical symptoms
[2].
The temporomandibular joint (TMJ) is composed of two bones,
the mandibular condyle and the glenoid fossa of the temporal bone
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faculty of medicine, university of Debrecen, 98, Nagyerdei street, 4032 Debrecen,
Hungary.
E-mail address: szekanecz.zoltan@med.unideb.hu (Z. Szekanecz).
1 Co-ﬁrst authors with equal contribution.
separated by a ﬁbro cartilaginous disc (Fig. 1). Compared to other
joints in the body, TMJ exerts unique properties as it is exposed
only to limited load-bearing forces [3] and it has different mor-
phological, functional, biomechanical and biological features [4].
Histologically, the most superﬁcial cellular layer is a ﬁbrocartilage,
primarily consisting of type I collagen (CI), whilst the remaining
deeper cellular zones contain type II collagen (CII) [5]. This is a
unique feature of the TMJ compared to other joints containing hya-
line cartilage, which are made entirely of CII. The developmental
origin of the ﬁbrocartilage of the TMJ is also different compared to
the origin of hyaline cartilage as it develops independently from the
chondroskeleton. The cartilage has two roles, it acts as an articular
joint cartilage and also as a site for enchondral ossiﬁcation. Con-
sequently, compared to other joints, it is more likely that cellular
events occurring within the TMJ cartilage and subchondral bone
may inﬂuence tissue homeostasis [6].
In mice, the mandibular condyle reaches skeletal maturity by
the eight postnatal week. Until the end of development, the condy-
lar articular surface covers 4-5 rows of ﬂattened ﬁbroblasts. Above
and below this level, light microscopic investigations revealed
the presence of CI. By 8 weeks, the articular surface presents a
smooth outline, but there are marked changes in the internal
organization of various cell types including decrease in the num-
ber of progenitor cells. Immediately following skeletal maturation,
the entire condyle undergoes pronounced remodelling, showing
http://dx.doi.org/10.1016/j.jbspin.2016.05.016
1297-319X/© 2016 Published by Elsevier Masson SAS on behalf of Socie´te´ franc¸aise de rhumatologie.
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Fig. 1. Anatomical sketch of the temporomandibular joint.
marked alteration of its internal and external architecture. With
the advancement of age, there is qualitative decrease in PG con-
tent. A layer of amorphous material appears over the articular
surface and there is increased surface labelling with colloidal iron
accompaniedby changes in the appearanceof the collagenous com-
ponent of the tissue. Collagen ﬁbres become closely packed and
change their orientation. Light microscopic investigations revealed
that with increasing age, the cartilage was reduced to a thin cres-
centic band. The articular surface at this stage still has a smooth
outline, and the number of surface cells reduces and their shape
becomes rounded. These cells are still evenly distributed though.
In the deeper layer, there are unevenly distributed hypertrophic
cells separated by a large amount of extracellular matrix (ECM).
The distance between the articular cartilage and the underlying
vasculature is decreased. These cells lack deep metachromasia. At
7 months, almost all mice of this strain develop arthropathy in
the TMJ [7]. First, there is failure of staining with acidic toluidine
blue and clustering of chondrocytes is observed. Later, the articu-
lar surface becomes irregular, and superﬁcial clefts appear. In more
advanced stages, deeper cracks develop and the articular surface
loses ﬁbrocartilage. The articular space decreases as a result of
ﬁbrous ankylosis of the joint [8].
2. Murine TMJ OA models
There are multiple TMJ OA models indicating that the patho-
genesis of OA has not yet been fully elucidated. These models
range from surgical procedures to genetic manipulations. There
are also idiopathic models: C57BL/6S mice develop spontaneous
OA from 12weeks of age. At 24–36weeks, clefts in the carti-
lage layer is observed along with reduction in the number and
irregular alignment of chondrocytes accompanied by detachment
or disappearance of the ﬁbrous layer. From 36weeks, formation of
chondrocyte clusters and growth of cells in the synovial membrane
toward the surface of the cartilage have been noted. By 72weeks,
deep clefts develop in the bone, the presence of osteophytes and
partial detachment of the chondrocyte layer become characteristic
feature [9]. It is known that obesity is a major risk factor for the
development of OA in both weight bearing and non-weight bear-
ing joints. However, unlike in the knee joint, C57BL/6J mice show
no signiﬁcant cartilage loss in the TMJ when compared to mice on
normal diet, indicating that the adipose associated inﬂammation
does not contribute to the OA in TMJ [10].
Partial discectomy of the TMJ results in articular degeneration
starting from 4 weeks. Chondrocyte clusters appear at 9weeks, PG
staining andﬁbrillation of cartilage at 12weeks and loss of articular
cartilage by 16weeks [11]. Primary OA-like disease develops by
the age of 7months in ICR mice after injection of triamcinolone
diacetate for 8 consecutive weeks [8].
Mutations in the genes coding for CII (COL2A1), CIX (COL9A1,
COL9A2 and COL9A3) and CXI (COL11A1 and COL11A2) are respon-
sible for early onset OA associated with variable degrees of
chondrodysplasia in humans [12]. Several murine gene-deﬁcient
(“knockout” [KO])models have beenproduced,which resemble the
above diseases. Deletion in the COL2A1 gene disturbs the assembly
and processing of the homotrimeric CII molecule in the carti-
lage resulting in severe chondrodysplastic phenotype with short
limbs, hypoplastic thorax, abnormal craniofacial development and
other skeletal deformities. The mutation interferences with nor-
mal enchondral ossiﬁcation [13]. There is reduced number of small
chondrocytes in an unorganized setting in the TMJ of these mice,
which results in the cartilage being sealed off by bone. By 3months,
the height of the condylar cartilage is decreased, the chondrocytes
form clusters and became disorganized. At 6months, the carti-
lage is decreased and small areas without chondrocytes become
visible and the normal columnar arrangement of chondrocytes in
the osteochondral junction is also disturbed. At 9months, there
is intra-articular ﬁbrous adhesion between the condylar articu-
lar surface and the disc and vertical splits between chondrocytes
became apparent. The columnar appearance is completely dimin-
ished by this time. By 15months, the condyles are largely resorbed
and the condylar surface is covered with ﬁbrotic tissue or the joint
is fused [14]. CVI-deﬁcient (COL6A1-KO) mice also develop early
onset OA but other than smaller stature and slower ossiﬁcation,
there are no apparent abnormalities. The collagen of these mice
shows signiﬁcantly reduced mechanical properties [15]. Homozy-
gous mutant mice lacking CIX (inactivated COL9A1 gene) show no
detectable abnormalities, but develop early onset OA in the knee
joints [16]. CXI-deﬁcient (COL11A1-KO) mice also develop OA-like
degenerative changes in the knee and TMJ. These changes start at 3
months but become more severe as time passes. This defect is also
associatedwith increased production ofmatrixmetalloproteinases
(MMP-3 and MMP-13) in the joints [12].
Biglycan and ﬁbromodulin are also key players in regulating
chondrogenesis and ECM turnover during the development of TMJ
OA pathology. As transforming growth factor 1 (TGF-1) binds to
these proteins, in their absence, TGF-1 accumulates which leads
to overactive signal transduction leading to increased chondrogen-
esis andECMturnover. As a result,mice lacking theseproteins show
abnormal growth and differentiation of condylar chondrocytes and
accelerated aggrecan content loss in the mandibular cartilage lead-
ing to TMJ OA [4,17].
Col1-IL1XAT transgenic mice overexpress interleukin 1 (IL-
1) in the TMJ. These mice are characterized by most features of
OA associated with orofacial grooming and decreased resistance to
mouth opening suggesting joint pain and dysfunction [18].
3. The role of cytokines in murine models of TMJ OA
TGF- is a secretory polypeptide, which acts as a paracrine
regulator of cell proliferation and ECM formation [19]. TGF-1
is a potent regulator of chondrogenesis and plays an essential
role during OA pathology [4]. ECM controls the formation and
degradation of TMJ condylar cartilage by regulating availability of
active TGF-1. TGF-1 increases the proliferation of mesenchy-
mal chondroprogenitor cells (MCCs) [20], induces expression of
transcription factors Sox5, Sox6 and Sox9, which are critical for
chondrogenesis. It also stimulates the expression of ECM genes
including those of aggreccan (AGG), CII (COL2A1) and CX (COL10A1)
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[4]. In the bone, TGF-1 increases proliferation and ECM synthe-
sis by osteoblasts, inhibits of the synthesis of cartilage degrading
enzymes and induces theproduction of tissue inhibitors ofmetallo-
proteinases (TIMPs). This growth factor also inhibits thedestructive
effects of IL-1 on the ECM. As described above, biglycan and ﬁbro-
modulin bind to members of the TGF superfamily and regulate
their effects on bone marrow stroma cells, osteoblasts and ten-
don stem/precursor cells by sequestering the growth factorswithin
the ECM [21]. Mice deﬁcient in biglycan and ﬁbromodulin exhibit
sequestration of TGF-1 in the ECM leading to overactive signal
transduction. First, it results in induced chondrogenesis, CII and
aggrecan production but ultimately it leads to imbalance in ECM
turnover, loss of CII and aggrecan leading to degradation of the car-
tilage. These changes present earlier in these gene-deﬁcient mice
than in their wild type counterparts [4]. Other investigators found
that the stimulatory/inhibitory effect of TGF-1 depended on its
concentration: TGF-1 exerts inhibitory effects at lower concen-
trations, while it is stimulatory at higher levels [20]. ADAMTS are
major aggracanases and play a pivotal role in OA of other joints
[22,23]. TGF-1 also up regulates ADAMTS4 leading to the cleavage
of aggrecan [24]. TGF-1 acts synergisticallywith other growth fac-
tors, such as insulin-like growth factor 1 (IGF-1) [19]. In advanced
TMJ OA, IGF-1 is upregulated in order to induce repair processes
[25]. Cultures of MCC explants supplemented with TGF-, TGF-
+IGF-1 or growth hormone (GH) show increased height and area
of toluidine blue staining indicating the presence of cartilage pro-
duction [26].
IL-1 and IL-1 are catabolic cytokines, which has an inhibitory
effect on cell proliferation, ECM synthesis and alkaline phosphatase
(ALP) production [20]. Increased IL-1 levels have been associated
with the development of joint pathology in OA. There may be an
inverse correlation between TGF- and IL-1 production during
the development of joint pathology. Low levels of TGF- have been
associated with high levels of IL-1, and vice versa. This occurs
through inhibition of TGF- expression through the IL-1RI recep-
tor. Abrogation of IL-1 signalling in IL-1RI-KO mice prevented the
development of OA [27]. As mentioned above, Col1-IL1XAT trans-
genic mice overexpress IL-1 in their TMJ. Pathologic changes in
these mice occur the articular cartilage but not the in the bone.
These changes include superﬁcial ﬁbrillations, articular surfaceero-
sions and chondrocyte cloning accompanied by and apparent loss
of PGcontent. There is inductionofmediatorsof inﬂammationasso-
ciated with cartilage destruction including IL-6, cyclooxygenase 2
(COX-2) and MMP-9 [18].
4. The role of biglycan and ﬁbromodulin
As described above, biglycan and ﬁbromodulin are members
of the small leucine-rich repeat PG family (SLRPs) and are highly
expressed in bone, tendon and cartilage. The ECM is important in
maintaining the mandibular condylar cartilage integrity. Biglycan
and ﬁbromodulin are important in regulating chondrogenesis and
ECM turnover during TMJ OA pathology. These SLRPs are able to
maintainECMstructureby interactingwith thenetworkof cartilage
proteins and can mediate cell metabolism by binding to members
of the TGF- superfamily [21,28]. Both biglycan and ﬁbromodulin
bind toTGF-1andcause sequestrationof this growth factorwithin
the ECM [28]. Deﬁciency of the BGN or FMOD gene in mice leads
to increased free active TGF-1 in the condylar cartilage, which
results in increased TGF-1 signalling in MCCs. Abundant TGF-1
signalling in the absence of BGN and FMOD increases turnover in
mandibular condylar cartilage by increasing both ECMprotein syn-
thesis, as well as degradation by MMPs [4,6]. The degradation of CII
but not that of aggrecan is a key feature of TMJ OA [6]. The switch to
MCC degeneration dominance over formation occurs much earlier
than in wild type mice leading to early onset OA in TMJ [4].
BGN- or FMOD-KO mandibular condylar cartilage exerts
increased cellularity compared with wild-type cartilage and has
expanded articular and mature zones. The hypercellularity is likely
attributable to increased proliferation of MCCs. The expression of
CII is 1.6-fold, while that of aggrecan is 4.2-fold higher than inwild-
type MCCs. There is also increased expression of AGG, COL2A1 and
COL10A1 genes. The accelerated loss of aggrecan content is due to
increased degradation of this protein by aggrecanases [6]. There is
alsoa redistributionofCII as theexpressionofCII is localiseddistally
from the articular surface, which indicates that the articular zone is
expanded. CI levels are also higher but this is accompanied bymore
extensive degradation of this protein. Increased toluidine blue and
safranin O staining indicates higher amount of PG deposition in the
ECM. There is also notable CX expression in gene-deﬁcient, but not
in thewild typemice. The glucosaminoglycan (GAG) content is sim-
ilar in KOandwild type animals at 12weeks, however, GAG content
becomes signiﬁcantly decreased by 32weeks in the BGN/FMOD-KO
mice [29]. Apoptosis of chondrocytes in the mandibular condyle
is more pronounced in the absence of biglycan and ﬁbromodulin.
Suppressed chondrogenesis may not be an important contribut-
ing factor in TMJ OA pathology seen in BGN/FMOD-KO animals.
However, there is decreased amount of bone in the subchondral
bone region of the TMJ in mice as a result of increased osteoclast
(OC) activity and bone turnover. As a consequence of high bone
turnover, there is defective trabecular bone structure formation in
the subchondral region, which may be a relevant contributor to OA
pathology [29] (Tables 1 and 2). Q2
Altogether 22 genes show differential expression in the TMJs
of BGN/FMOD-deﬁcient mice. Down-regulated genes coding for
other ECM proteins involved in cartilage degeneration include pro-
collagen type IX 3, procollagen type II 1, procollagen type IX
1, as well as matrilin 3. At least ﬁve genes exert differential
expression, which are related to osteoclast function/differentiation
and bone turnover. These include genes of CART prepropeptide,
secreted frizzled-related sequence protein 1 (SFRP1), arylsulfatase
K, solute carrier family 4 member 1 (SCF4M1) and protein tyrosine
phosphatase receptor type V. CART prepropeptide inhibits bone
resorption by modulating RANKL expression, while SCF4M1 is a
criticalmediatorofbothosteoclastdifferentiationand function. The
disruption of bone and cartilage metabolism in younger mice could
disrupt the overall TMJ tissue homeostasis. This predisposes the
mice to late-onset TMJ OA that is associated with osteophyte for-
mation, TMJ subchondral bone sclerosis and cartilage degeneration
[6,14,17,29].
5. The role of various types of collagen in murine models of
TMJ OA
Several murine gene-deﬁcient models have been developed
that resemble OA in TMJ and other joints. Among various types
of collagen, deletion in the COL2A1 gene disturbs the assembly
and processing of the homotrimeric CII molecule within the car-
tilage. Homozygous COL2A1-KO mice have short axial skeleton and
develop respiratory distress, which results in perinatal death. Het-
erozygousCol2A1+/−miceexert smaller stature, hypoplastic chest,
abnormal craniofacial development and other skeletal deformities
compared to wild type mice. This mutation interferes with nor-
mal enchondral ossiﬁcation. The amount of cartilage at the cranial
base is also reduced. These mice have severe defects in their TMJ.
They develop progressive OA lesions from the age of six months.
Features of TMJ OA include shorter synchondroses, deranged orga-
nisation of cells, reduction of the number and size of chondrocytes
and decreased amount of ECM in the TMJs [13,14].
CVI-deﬁcient (COL6A1 −/− and +/−) mice also develop early
onset OA but, other than smaller stature and slower ossiﬁcation,
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Table 1
Mouse strains and phenotypes.
Mouse strains Effect
Type II collagen Col2A1 −/−
Col2A1 +/−
Homozygous: short axial skeleton; respiratory distress; perinatal death
Heterozygous: smaller stature; size of cartilaginous structures of the cranial base reduced; severe
TMJ defects, progressive OA lesions from six months; shorter synchondroses; deranged
organisation of cells; reduction of number and size of chondrocytes and amount of ECM
Type VI collagen Col6A1 −/−, +/− No apparent abnormalities
Lower body weight
Reduced mechanical properties of collagen
Accelerated age dependent OA
Delayed ossiﬁcation and reduced mineral density
Lower linear elastic behaviour
Type IX collagen Col9a1 −/− Early OA starting at the age of three months
Normal development
Type XI collagen Col11a1 (cho)+/− Homozygous: lethal
Heterozygous: normal development, no skeletal abnormalities at birth; early OA starting at three
months of age
TGF- In the cartilage: chondrogenesis regulator; increases MCC proliferation; stimulates ECM genes
increases expression of transcription factors
In the bone: osteoblast ECM synthesis; cartilage degrading enzyme inhibitor; TIMP inductor;
inhibits destructive effect of IL-1 on ECM; biglycan and ﬁbromodulin binds to it; up regulates
ADAMTS4 leading to cleavage of aggrecan; synergistic with IGF-1
IL-1 IL-1 KO
Col1-IL1XAT
Inhibitory effect on cell proliferation
ECM synthesis
ALP production
IL-1RI-KO mice: no development of OA; Col1-IL1XAT mice
Overexpress IL-1
Superﬁcial ﬁbrillations
Articular surface erosions
Apparent loss of PG content
Biglycan and Fibromodulin Double KO mice Interacts with the network of cartilage proteins
Mediate cell metabolism by binding to members of the TGF-1 which results in sequestration in
the ECM
Double KO mice: early onset OA; increased condylar cartilage cellularity (increased proliferation
of MCCs); increased expression of AGG, COL2A1 and COL10A1 genes; increased degradation of
aggreccan by aggreccanases; CI degradation; redistribution of CII; CX expression; reduced GAG
content by 32 weeks; pronounced apoptosis of chondrocytes; decreased amount of bone in the
subchondral region as a result of increased osteoclast activity and bone turnover; defective
trabecular bone formation
there are no apparent abnormalities. The collagen of these mice
shows signiﬁcantly reduced mechanical properties and lower
linear elastic behaviour. Delayed ossiﬁcation and reduced bone
mineral density is also characteristic for these mice [15].
Homozygous mutant mice lacking the CIX (COL9A1) gene exert
no detectable abnormalities, but develop early onset OA in the TMJ
and knee joints starting at the age of threemonths. Otherwise these
animals exhibit normal development [16,30].
CXI (COL11A1) homozygous mutation is lethal in mice. Ani-
mals showing heterozygous mutations (COL11A1 +/−) have normal
development and theyhaveno skeletal abnormalities at birth, how-
ever, they develop early OA-like degenerative changes by three
months of age in the knees and TMJs. These changes become more
severe with age. This genetic defect has also been associated with
increased MMP-3 and MMP-13 production and ECM degradation
in the knee joints [12,31].
Table 2
Matrix metalloproteinases.
MMP Role Localization
MMP-1 Not present in mice
MMP-2 Early role in growth and housekeeping of normal cartilage
turnover
Young: chondroblastic and hypertrophic zones
Old: articular surface, in cartilage
MMP-3 OA if abundant production Detected at all times: young: immature chondrocytes in the chondroblastic
and hypertrophic zones; old: articular surface, chondroblastic zone and in the
hypertrophic zone
MMP-8 Collagen cleaving enzyme Young: chondroblastic and articular surface zones
Older: all regions
MMP-9 Removal of denatured collagen fragments Constant presence in the joint (IL-1 upregulates production): young: articular
surface, hypertrophic zones and in the resorption front; old: along articular
surface and cartilage
MMP-13 Resorption and bone formation via enchondral ossiﬁcation
at the cartilage-bone interface
Cartilage-bone interface
TIMP-1 MMP inhibition Young:articular surface, chondroblastic zone and resorption front
Old: all zones
TIMP-2 MMP inhibition Young: not at articular surface
Old: articular surface and chondroblastic zones
HTRA1 Degrades molecules of pericellular matrix. Disrupts the
pericellular matrix network which alters chondrocyte
metabolism resultion in OA
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6. The role of proteolytic enzymes in murine models of TMJ
OA
MMPs are important for the remodelling of ECM by degrading
collagen, PGs and other components of the ECM [32]. There are over
20 known MMPs. These proteases are secreted in inactive form
and are activated by the ECM milieu. There are three subgroups
of these enzymes: 1) collagenases, which degrade CI, CII and CIII
(MMP1, MMP8 and MMP13), 2) stromelysins that digest PG and
nonhelical regions of collagens (MMP3 and MMP11), as well as 3)
gelatinases speciﬁc for degraded collagen and also for collagenase-
resistant collagens, such as CIV, CV, CXI (MMP2, MMP9) [19,33].
The distribution pattern of the various MMPs shows high variabil-
ity even within the same class of enzymes, which suggest speciﬁc
but overlapping functions [34]. Expressions of MMPs are regulated
on both transcriptional and post-translational levels by growth
factors, cytokines and TIMPs [33,35]. Loss of balance of this regula-
tion can lead to proteolysis and joint degradation. MMP and TIMP
activities, as well as the ratio of various MMPs/TIMPs are essen-
tial for physiological remodelling of the articular cartilage and for
ECM destruction in disease processes. Higher activities of MMPs at
younger age are characteristic for rapid growth and differentiation
[36].
Among the various MMPs, no MMP-1 mRNA has been detected
in the TMJ or knee joints of mice. MMP-2 has a role in the early
stages of growth and has a housekeeping function of normal car-
tilage turnover. Traces of MMP-2 mRNA have been detected in
newborns. MMP-2 expression peaks at 2 weeks and decreases
thereafter. This decrease inmRNA levels is followedby thedecrease
of MMP-2 protein expression. Both the active and latent forms of
MMP-2 protein were detected in the TMJ and the knee joints from
birth. In newborn and young animals, MMP-2 is localized in chon-
droblastic and hypertrophic zones and can be detected earlier than
MMP-9. The activity of MMP-2 is reduced during maturation and
aging and at 18 months of age it can be detected along the articular
surface and within the cartilage [33,37].
Abundant production of MMP-3 has been associated with OA
[38]. In the TMJ, MMP-3 mRNA expression is prominent through-
out postnatal development and aging, whilst in the knee joint it is
low in newborn and aged animals but high in two-week-old ani-
mals.MMP-3expression is detected at all timepoints in these joints
[39,40].MMP-3protein expressionat threeweeksof age is conﬁned
to immature chondrocytes in the chondroblastic and hypertrophic
zones, and is less pronounced at the articular surface. At the age of
18months, MMP-3 is expressed along the articular surface, in the
chondroblastic zone and in the hypertrophic zone [12,34,41].
MMP-8 is a collagen-cleaving enzyme, which is present in the
connective tissueofmostmammals. Inyounganimals, it is localized
to the chondroblastic and to the articular surface zones, in older
animals it can be detected in all regions of the TMJ [42].
The role of MMP-9 is removal of denatured collagen fragments
that increase with deterioration of cartilage in aging joints [33].
The expression of MMP-9 mRNA is consistent with that of MMP-9
protein levels at birth and in young animals. However, whilemRNA
levels decrease in older animals,MMP-9protein levels remainhigh.
One reason for that might be the age-related elevation of pro-
inﬂammatory cytokine (e.g. IL-1) production. These cytokines are
constantly present in the synovial ﬂuid of aging joints and theymay
up-regulate the expression of MMP-9 [43]. Compared to the knee
joint, MMP-9 levels in the TMJ are higher in newborn and young
animals. At this stage, MMP-9 can be detected at the articular sur-
face, in hypertrophic zones and in the resorption front. Levels are
lower in the chondroblastic zone. The amount of MMP-9 decreases
during later phases of development, when it can be detected along
the articular surface and in the cartilage. In general, MMP-9 levels
are lower than MMP-2 in the TMJ [34,41].
MMP-13 cleaves CII. It is expressed in skeletal tissues where it
participates in both collagen and PG degradation in hypertrophic
chondrocyte-calcifying ECM [39,44,45]. In normal cartilage, MMP-
13 is expressed at a very low level and it may be associated
with resorption and bone formation via enchondral ossiﬁcation at
the cartilage-bone interface [46–48]. High levels of MMP-13 have
been described in osteoarthritic cartilage. Constitutive expression
of MMP-13 results in OA-like changes in mouse knee joints [11].
Higher expression of MMP-13 has been noted in COL9A1-KO mice
[30]. In addition, abundant production of both MMP-3 and MMP-
13 has been detected in COL11A1-KOmice [12]. MMP-13 mRNA is
expressed throughout the development of OA [39,40]. Levels are
lower in the knee joint at birth and it peaks at two weeks of age. In
older animals, there is lower expression of MMP-13 in all regions
[34,41]. In mice experiencing early-onset TMJ OA as a result of par-
tial TMJ discectomy, increased expression of MMP-13 was found
likely due to elevated expression of discoidin domain receptor 2
(DDR-2) [49]. DDR-2 is a cell membrane tyrosine kinase receptor
that preferentially binds to native CII. Under normal conditions,
there is little of no CII around chondrocytes in the pericellular
region, which means that there is no contact between chondro-
cytes and CII in healthy mature articular cartilage [11]. Exposure
of the collagen network to chondrocytes will permit interaction of
CII with these cells resulting in activation of DDR-2. The activated
DDR-2 induces the expression of MMP-13 [11,49,50]. The expres-
sionof bothMMP-13andDDR-2was increased8weeks after partial
discectomy,when degradation of PGwas already evident. This sug-
gests that inhibitors of DDR-2 might be useful for the treatment of
OA [11,49]. Mice deﬁcient in CIX and CXI also exhibit early OA as
a result of increased DDR-2 and MMP-13 at 6months of age both
in the knees and in the TMJs suggesting that deﬁciency of these
collagens may have deleterious effects on the non-weight-bearing
joints as well [30,50]. Expression of high temperature require-
ment factor A1 (HTRA1) mRNA is increased in the TMJ in CIX-KO
and CXI-haploinsufﬁcient mice, as well as in mice that underwent
TMJ discectomy. HTRA1 is a serin protease [51] that disrupts the
pericellular matrix network, which alters chondrocyte metabolism
resulting in OA. Expression of HTRA1 has also been associated with
expression of DDR-2 in chondrocytes [52].
TIMP-1 in young mice is located in the articular surface, chon-
droblastic zone and at the resorption front, while TIMP-2 is not
present at the articular surface. In 18-month-old animals, TIMP-
1 can be detected in all zones whilst TIMP-2 is conﬁned to the
articular surface and to the chondroblastic zones in TMJ [53].
7. TMJ involvement in other murine arthritis models
Mice injected intravenously with Staphylococcus aureus develop
septic arthritis in the TMJ four days after inoculation. Already at
2days after inoculation, there are dilated capillaries in the dis-
cal attachments, cocci on articular surfaces and neutrophils and
macrophages are visible in the condylar marrow. At 4days, there
are acute inﬂammatory signs, collagen ﬁbers on the surface of the
disc and structural changes in the condyles. Two weeks later, there
are minor transverse ﬁssures in the ﬁbrous layer of the condyle.
Deeper layers of the discs become involved. Later, collagen ﬁbers
in thedisc andcondylar surfacebecomedisrupted, and there is lym-
phocyte inﬁltration in the bone marrow. Chondrocytes continue to
degenerate. Bacteria enter the joint through the synovial vessels
[54].
There is little or no synovial inﬂammation in the TMJ of mice
with PG-induced arthritis (PGIA) [55]. Mice with PGIA develop OA-
like damage in the cartilage of this joint. The structural damage
is mediated by aggrecanases and MMPs through loss of GAG-
containing aggrecan. This is thought to be due to the constantly
elevated levels of catabolic cytokines in the circulation, which
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results in a pro-inﬂammatory milieu in the TMJ leading to up
regulation of proteolytic enzymes and loss of aggrecan from the
cartilage [56].
Adjuvant-induced arthritis (AIA) has originally been described
in rats [57], however, injection of Freund’s adjuvant also causes TMJ
arthritis in mice [53]. In this model, there are microscopic signs of
arthritis three weeks after administration of adjuvant to the scalp
and to the base of the tail [57].
MRL/l mice develop spontaneous immune arthropathy that
resembles rheumatoid arthritis (RA) associated with synovial peri-
articular and perivascular inﬂammation, pannus and articular
erosion, subcutaneous periarticular inﬂammation and synovial
exudates [58]. Arthritis can also be observed in the TMJ, however,
this joint is less often involved and the articular changes are also
less severe [59].
Bilharziasis can cause arthropathy in theTMJ.Mice infectedwith
this disease show massive chronic inﬂammatory cell inﬁltration,
articular disk thickening, hyperplastic changes with narrowing of
the joint space and articular surface erosions in the TMJ [60].
8. Conclusions
Osteoarthritis of the TMJ is a multifactorial disease. Different
types of collagens,matrixmetalloproteinases, SLRPs, cytokines and
lifestyle choices all contribute to its early development but ulti-
mately all mice develop osteoarthritis in the TMJs. Further studies
are necessary to enhance our understanding of the disease and to
develop ways to delay its onset.
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